A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol
Abstract Background Many patients with head and neck cancer are not candidates for standard of care definitive treatments though often require palliative treatments given the frequent symptoms associated with head and neck cancer. While existing palliative radiotherapy regimens can provide adequate...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13303-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133151588810752 |
|---|---|
| author | P. Travis Courtney Milisuryani L. Santoso Ricky R. Savjani Vishruth K. Reddy Wanxing Chai-Ho Maria A. Velez Velez Deborah J. Wong Christy Palodichuk T. Vincent Basehart Dylan P. O’Connell Minsong Cao Donatello Telesca Robert K. Chin |
| author_facet | P. Travis Courtney Milisuryani L. Santoso Ricky R. Savjani Vishruth K. Reddy Wanxing Chai-Ho Maria A. Velez Velez Deborah J. Wong Christy Palodichuk T. Vincent Basehart Dylan P. O’Connell Minsong Cao Donatello Telesca Robert K. Chin |
| author_sort | P. Travis Courtney |
| collection | DOAJ |
| description | Abstract Background Many patients with head and neck cancer are not candidates for standard of care definitive treatments though often require palliative treatments given the frequent symptoms associated with head and neck cancer. While existing palliative radiotherapy regimens can provide adequate symptom control, they have limitations particularly with respect to local control which is becoming more important as advances in systemic therapy are improving survival. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) is a novel radiotherapy regimen which leverages advances in radiotherapy treatment technology and extended interfraction intervals to enable adaptive radiotherapy and possible synergy with the immune system. Additionally, HyperArc© (Varian Medical Systems, Inc.) radiotherapy planning software allows for safe dose-escalation to head and neck tumors. Methods This single-arm phase II study will prospectively evaluate PULSAR with HyperArc© software for palliative treatment of head and neck cancer. Patients with de novo or recurrent, localized or metastatic, head and neck cancer who are ineligible for or decline standard of care definitive treatments are eligible for enrollment. Forty-three patients will receive an 11 Gray fraction of radiation every two weeks for a total of five fractions and dose of 55 Gy. Adaptive radiotherapy planning is permitted. A safety and feasibility evaluation will be performed after enrollment of the first fifteen patients whereby the trial will be closed if five or more patients experience a CTCAEv5.0 grade 3 or 4 or any patient experiences a grade 5 toxicity probably attributable to PULSAR during or within three months after its completion. The primary endpoint is one-year local head and neck tumor control. Secondary endpoints include safety, disease progression-free and overall survival, symptomatic impact, frequency of re-simulation and/or adaptive planning, and radiation dosimetry of PULSAR. Additionally, enrolled patients are permitted to receive cancer-directed systemic therapy, including immunotherapy, during PULSAR which may allow for the analysis of the safety and efficacy of this combination. Discussion The PULS-Pal trial is the first prospective study of PULSAR with HyperArc© software for head and neck cancer. We hypothesize that this radiotherapy regimen will lead to improved local tumor control compared with historical controls in patients undergoing palliative radiotherapy for head and neck cancer. Trial registration Clinicaltrials.gov identifier: NCT06572423 . Date of registration: August 28th, 2024. |
| format | Article |
| id | doaj-art-385c0bd657934300b98383e09de6bb80 |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-385c0bd657934300b98383e09de6bb802025-08-20T02:32:03ZengBMCBMC Cancer1471-24072024-12-0124111610.1186/s12885-024-13303-5A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocolP. Travis Courtney0Milisuryani L. Santoso1Ricky R. Savjani2Vishruth K. Reddy3Wanxing Chai-Ho4Maria A. Velez Velez5Deborah J. Wong6Christy Palodichuk7T. Vincent Basehart8Dylan P. O’Connell9Minsong Cao10Donatello Telesca11Robert K. Chin12Department of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Medical Oncology, University of CaliforniaDepartment of Medical Oncology, University of CaliforniaDepartment of Medical Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaDepartment of Biostatistics, Fielding School of Public Health, University of CaliforniaDepartment of Radiation Oncology, University of CaliforniaAbstract Background Many patients with head and neck cancer are not candidates for standard of care definitive treatments though often require palliative treatments given the frequent symptoms associated with head and neck cancer. While existing palliative radiotherapy regimens can provide adequate symptom control, they have limitations particularly with respect to local control which is becoming more important as advances in systemic therapy are improving survival. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) is a novel radiotherapy regimen which leverages advances in radiotherapy treatment technology and extended interfraction intervals to enable adaptive radiotherapy and possible synergy with the immune system. Additionally, HyperArc© (Varian Medical Systems, Inc.) radiotherapy planning software allows for safe dose-escalation to head and neck tumors. Methods This single-arm phase II study will prospectively evaluate PULSAR with HyperArc© software for palliative treatment of head and neck cancer. Patients with de novo or recurrent, localized or metastatic, head and neck cancer who are ineligible for or decline standard of care definitive treatments are eligible for enrollment. Forty-three patients will receive an 11 Gray fraction of radiation every two weeks for a total of five fractions and dose of 55 Gy. Adaptive radiotherapy planning is permitted. A safety and feasibility evaluation will be performed after enrollment of the first fifteen patients whereby the trial will be closed if five or more patients experience a CTCAEv5.0 grade 3 or 4 or any patient experiences a grade 5 toxicity probably attributable to PULSAR during or within three months after its completion. The primary endpoint is one-year local head and neck tumor control. Secondary endpoints include safety, disease progression-free and overall survival, symptomatic impact, frequency of re-simulation and/or adaptive planning, and radiation dosimetry of PULSAR. Additionally, enrolled patients are permitted to receive cancer-directed systemic therapy, including immunotherapy, during PULSAR which may allow for the analysis of the safety and efficacy of this combination. Discussion The PULS-Pal trial is the first prospective study of PULSAR with HyperArc© software for head and neck cancer. We hypothesize that this radiotherapy regimen will lead to improved local tumor control compared with historical controls in patients undergoing palliative radiotherapy for head and neck cancer. Trial registration Clinicaltrials.gov identifier: NCT06572423 . Date of registration: August 28th, 2024.https://doi.org/10.1186/s12885-024-13303-5Head and neck cancerStereotactic body radiotherapy (SBRT)Personalized Ultrafractionated stereotactic adaptive radiotherapy (PULSAR)Palliative radiotherapy |
| spellingShingle | P. Travis Courtney Milisuryani L. Santoso Ricky R. Savjani Vishruth K. Reddy Wanxing Chai-Ho Maria A. Velez Velez Deborah J. Wong Christy Palodichuk T. Vincent Basehart Dylan P. O’Connell Minsong Cao Donatello Telesca Robert K. Chin A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol BMC Cancer Head and neck cancer Stereotactic body radiotherapy (SBRT) Personalized Ultrafractionated stereotactic adaptive radiotherapy (PULSAR) Palliative radiotherapy |
| title | A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol |
| title_full | A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol |
| title_fullStr | A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol |
| title_full_unstemmed | A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol |
| title_short | A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol |
| title_sort | phase ii study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment puls pal a single arm clinical trial protocol |
| topic | Head and neck cancer Stereotactic body radiotherapy (SBRT) Personalized Ultrafractionated stereotactic adaptive radiotherapy (PULSAR) Palliative radiotherapy |
| url | https://doi.org/10.1186/s12885-024-13303-5 |
| work_keys_str_mv | AT ptraviscourtney aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT milisuryanilsantoso aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT rickyrsavjani aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT vishruthkreddy aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT wanxingchaiho aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT mariaavelezvelez aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT deborahjwong aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT christypalodichuk aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT tvincentbasehart aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT dylanpoconnell aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT minsongcao aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT donatellotelesca aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT robertkchin aphaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT ptraviscourtney phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT milisuryanilsantoso phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT rickyrsavjani phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT vishruthkreddy phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT wanxingchaiho phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT mariaavelezvelez phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT deborahjwong phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT christypalodichuk phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT tvincentbasehart phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT dylanpoconnell phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT minsongcao phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT donatellotelesca phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol AT robertkchin phaseiistudyofpersonalizedultrafractionatedstereotacticadaptiveradiotherapyforpalliativeheadandneckcancertreatmentpulspalasinglearmclinicaltrialprotocol |